Hypertensive pulmonary vascular disease: Dawn of the age of prevention?

American Journal of Respiratory and Critical Care Medicine

Volumn 162, Issue 6, 2000, Pages 2020-2021

  Newman, J H ^a   Lane, K B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIN; ENDOTHELIN RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCROTALINE; NITRIC OXIDE; PROSTACYCLIN; THROMBOXANE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIPTOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BLOOD VESSEL INJURY; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSFECTION; HERB; HUMAN IMMUNODEFICIENCY VIRUS; INTIMA; LIVER CIRRHOSIS; LUNG RESECTION; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REVIEW; SCLERODERMA;

EID: 0034521647     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.162.6.ed12-00c     Document Type: Review

References (6)

1. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats
2. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
3. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension
4. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene